-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although routine assessments of disease activity in Crohn's disease (CD) can be made through serum markers, abdominal CT imaging and endoscopy, markers with better prognostic value are needed to predict the prognosis of the disease.
It has long been thought that fatty visceral adipose tissue (VAT) associated with intestinal inflammation is a major feature of CD, and studies have reported a relatively high proportion of VATs in children with CD, whether obese or not, and associated with adverse outcomes.
a wide range of metabolic, biochemical, immune, inflammatory, and microbial level changes in adipose tissue, including secretion of bioactive molecules called fat factors.
, especially the active fat factor immune, affects a variety of inflammatory pathways.
, this study aims to explore whether serum fat factor levels and VAT can be used as predictors of disease prognosis and treatment effectiveness in newly diagnosed CHILDREN with CD.
researchers recruited CD patients between the ages of 6 and 20 and obtained their clinical and anthotic data.
the levels of fat factors were measured at 0, 6 and 12 months, respectively, after CD diagnosis and in the baseline (CP) of the control group.
the levels of visceral fat (VAT) with magnetic resonance imaging or computer lithography within 3 months of diagnosis.
the study included 104 patients with routine colonoscopy: 36 diagnosed with CD and 68 with control (CP).
levels of lipid antibiotics and lysolysase primary activator inhibitors (PAI)-1 were significantly higher than CP in patients diagnosed with CD.
VAT is similar between CD and CP.
CD patients who gradually upgraded to biologics had significantly higher baseline resistance levels at diagnosis than those who did not use biotherapy (29.8 ng / mL VS 13.8 ng / mL; P - 0.004).
levels ≥29.8ng / mL at the time of diagnosis are predicted to be 95% specific to biotherapy in the first year after diagnosis (sensitivity s 53%; area under curve s 0.82; P s 0.015).
levels at the time of diagnosis in patients with CD in children can predict the possibility of gradual escalation to biotherapy after 12 months, independent of VAT.
levels of antibiotics and PAI-1 in CD patients treated with biologics increased significantly compared to patients who did not use biologics.
.